Advanced nanoparticles for osteoarthritis: a review

Area of Science:

• Biomaterials Science
• Orthopedics
• Pharmacology

Background:

• Osteoarthritis (OA) is a prevalent degenerative joint disease causing pain and disability, particularly in aging populations.
• Current OA treatments face challenges due to poor drug bioavailability within the joint cavity.
• Developing targeted drug delivery systems is crucial for effective OA management.

Purpose of the Study:

• To review the recent advancements in using Poly(lactic-co-glycolic)-acid (PLGA) for drug delivery in osteoarthritis treatment.
• To provide a comprehensive perspective on PLGA-based therapeutic strategies for joint diseases.
• To explore the potential of PLGA in enhancing cartilage targeting and drug bioavailability.

Main Methods:

• Literature review of studies utilizing PLGA in osteoarthritis drug delivery.
• Analysis of PLGA's properties relevant to intra-articular drug delivery.
• Evaluation of research focusing on cartilage-targeting strategies with PLGA.

Main Results:

• PLGA demonstrates significant potential for improving drug delivery to the joint cavity.
• PLGA-based systems can enhance the bioavailability of therapeutic agents for osteoarthritis.
• Research indicates PLGA's suitability for developing targeted drug delivery for cartilage.

Conclusions:

• PLGA represents a promising biomaterial for developing advanced drug delivery systems for osteoarthritis.
• Targeted delivery using PLGA can overcome the bioavailability limitations of current OA treatments.
• Further research into PLGA-based therapies may lead to more effective treatments for arthritis patients.